AMBROSIA A Multiplexed Plasmo-Photonic Biosensing Platform For Rapid And Intelligent Sepsis Diagnosis At The Point-Of-Care
- Coordinator
- Aristotelio Panepistimio Thessalonikis, Greece
- Runs
- 1 January 2023 to 31 December 2026
- Status
- Running
- EU funding
- €3.7m
- Total cost
- €3.7m
- Partners
- 13 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101093166
What the project is doing
In the project's own words, from its summary on CORDIS.
AMBROSIA aims to provide the foundations for a multi-sensing future-proof Point of Care Unit for sepsis diagnosis offered by a CMOS compatible toolkit and enhanced by on-chip photonic neural network technology to provide an accurate and rapid diagnosis. AMBROSIA will be investing in the established ultra-small-footprint and elevated sensitivity of integrated plasmo-photonic sensors reinforced by the well-known on-chip slow-light effect and micro-transfer printed lasers and photodiodes on Si3N4, as well as the functional processing and classification portfolio of integrated photonic neural network engines, towards painting the landscape of the next-coming disruption in sensor evolution, tailoring them in System-in-Package prototype assemblies, with the sensors being cheap disposable pluggable modules that can rapidly and accurately diagnose sepsis at the bedside in clinical environments.
AMBROSIA targets to demonstrate a Point of Care Unit incorporating: i) a switchable sensor area array, with each sensor area facilitating a pluggable, 8-channel label-free plasmo-photonic sensor for sepsis diagnosis with a sensitivity over 130.000nm/RIU and a Limit of Detection below 10-8 RIU for each interferometric sensor, ii) an embedded Si3N4 photonic neural network processing and classifying at the same time the data from at least 7 biomarkers with zero-power providing in the first minutes an accurate and rapid diagnosis for sepsis, iii) Micro-transfer printed lasers and photodetectors on chip that will drastically decrease costs of both the sensing and neural network modules, and render the sensor arrays disposable.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Aristotelio Panepistimio Thessalonikis | Thessaloniki | Greece | Coordinator |
| Ligentec SA | Ecublens | Switzerland | Associatedpartner |
| Argotech AS | Nachod | Czechia | Participant |
| Biopix Dna Technology Anonymi Etairia | Heraklion | Greece | Participant |
| Panepistimio Ioanninon | Ioannina | Greece | Participant |
| Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca | Barcelona | Spain | Participant |
| Fundacio Institut Catala De Nanociencia I Nanotecnologia | Bellaterra (Barcelona) | Spain | Participant |
| Microliquid SL | Mondragon | Spain | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Third party |
| Universite Bourgogne Europe | Dijon | France | Participant |
| X-Celeprint Limited | Dublin | Ireland | Participant |
| Smart Photonics BV | Eindhoven | Netherlands | Participant |
| University of Southampton | Southampton | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI